A method for preparing the nicotine-containing powder includes dissolving a carrier in a solvent to form a first solution, where the carrier includes a biopolymer, a natural polymer, a synthetic polymer, a bulk sweetener, or any combination thereof; contacting the first solution with nicotine, a nicotine complex, a nicotine salt, or any combination thereof to form a second mixture; and spray drying the second mixture to form a plurality of particles that define the nicotine-containing powder. The method may further include adding at least one of a pH modifier and an antioxidant to the second mixture. When the solvent includes water, an inlet temperature ranges from 120° C. to 210° C. and an initial product temperature ranges from 25° C. to 100° C. When the solvent includes ethanol, the inlet temperature ranges from 65° C. to 180° C. and an initial product temperature ranges from 25° C. to 79° C.

This invention relates to a fixed-dose dry powder inhalation formulation comprising fluticasone propionate and albuterol sulfate, together with an α-lactose monohydrate carrier. In the formulation, the albuterol sulfate stabilises fluticasone propionate.

A process can be used for preparing nano- or microparticles containing a carrier-polymer and a biologically active ingredient. The process is a solvent emulsion process involving an organic phase (OP) and an aqueous phase (AP) to form an emulsion. In the case of an oil-in-water emulsion (O/W), the organic phase (OP) contains the biologically active ingredient dissolved or dispersed therein. Alternatively, in the case of a water-in-oil emulsion (W.sub.1/O), the aqueous phase (AP) contains the biologically active ingredient dissolved or dispersed therein. The organic phase (OP) is saturated with the salt-containing aqueous phase (AP) and vice versa.

The present disclosure is directed to formulations, devices, kits, and methods for treating or preventing motor symptoms associated with Parkinson's disease by injection of a microsphere formulation of apomorphine free base or a pharmaceutically acceptable a salt thereof, wherein injection can be from a pre-filled injector.

A drug delivery system comprises a porous, self-healing biodegradable polymer matrix having a ionic, charged, biopolymer and a pH modifying species disposed within the pores. An ionic macromolecule having the opposite charge binds the biopolymer and forms a nonsoluble polyelectrolyte complex. The molecular weight of the biopolymer, the self healing polymer matrix, the concentration of pore forming agent and the concentration of the pH modifying species are selected for optimal binding and release of the macromolecule.

Provided herein are pharmaceutical formulations of dry-powder bendamustine suitable for pharmaceutical use. Also provided are methods of producing dry-powder bendamustine. The pharmaceutical formulations can be used for any disease that is sensitive to treatment with bendamustine, such as neoplastic diseases.

The present specification provides methods and compositions for treating fibrosis, particularly pulmonary fibrosis. The pulmonary fibrosis may be idiopathic or arise following an infection of the lung. The lung infection can be by SARS-CoV-2. Lung function stabilizes or is improved as a result of treatment.

This application relates to nanoparticles, including nanoparticles derived from a plasma, and their use in the formation of conjugates. The nanoparticles can be stably conjugated to a wide variety of second species, forming conjugates which can be used, for example, in therapeutic, diagnostic and experimental methods.

Disclosed are crosslinked particles (e.g., microparticles) that are capable of storing and releasing drugs. The particles can be macroparticles, microparticles, or nanoparticles and can be composed of polyester backbones. The particles can be loaded with a drug. The particles can degrade in vivo to release the drug. The particles can be prepared by crosslinking functionalized polyester backbones and loaded with a given drug. The particles of the present disclosure can be injected with a syringe. In some embodiments, the particles of the present disclosure are administered in connection with a surgery and release the drug after the site of the surgery for a period of 1-6 months.

Methods and industrial scale set-ups for manufacturing spray-dried powders are provided. During the process, a solvent is used. The process is done batchwise such that the emulsification mass ratio is low when removal of the solvent is started. Preferred solvents are isopropyl acetate and ethyl acetate.